CBR looks at five UK start-ups which have been noticeably creating innovations and acquisitions in the AI market.
BenevolentAI
Industry: Scientific discovery/ Pharmaceutical R&D
Founded: 2013
CEO: Jerome Pesenti
BenevolentAI, which is based in London, is responsible for applying the AI technology in the human health and bioscience sectors.
In 2014, the company collected a total of £40 million in funding from both its existing investors and Woodford Investment Management LLP, which was then an incoming investor.
Content from our partners
The company is currently focused on diseases, such as neurodegeneration, orphan diseases and rare cancers, but have said it remains flexible in case any other opportunities are to arise, due to its artificial intelligence and machine learning capabilities.
BenevolentAI uses complex AI to look for patterns in scientific literature, already having managed to identify two potential drug targets for Alzheimer’s with the use of AI.
It also recently announced that it was the first European company to begin using deep learning AI supercomputer, NVIDIA DGX-1.
